Droxidopa (Northera)

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Neurogenic Orthostatic Hypotension

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also in development:Parkinson's Disease · Phase 3 · investigational in the US

Also approved (1)
JP
  • Droxidopa (Dainippon Sumitomo Pharma): frozen gait and dizziness on standing associated with Parkinson's disease, and orthostatic hypotension
Product first approved 1989sec.gov

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (7)
Neurogenic Orthostatic Hypotension
NCT01927055 · Chelsea Therapeutics
2013-11 – 2015-02 · Symptomatic Neurogenic Orthostatic Hypotension, Parkinson's Disease, Multiple Systems Atrophy, Pure Autonomic Failure, Dopamine Beta Hydroxylase Deficiency
What this study did
NCT01132326 · Chelsea Therapeutics
2009-01 – 2013-02 · Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency, Non-Diabetic Neuropathy, Neurogenic Orthostatic Hypotension
What this study did
NCT00738062 · Chelsea Therapeutics
2008-01 – 2010-12 · Neurogenic Orthostatic Hypotension, Non-Diabetic Autonomic Neuropathy, Multiple System Atrophy, Dopamine Beta Hydroxylase Deficiency
What this study did
NCT00782340 · Chelsea Therapeutics
2008-09 – 2010-09 · Symptomatic Neurogenic Orthostatic Hypotension (NOH), Non-diabetic Neuropathy, Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency
What this study did
NCT00633880 · Chelsea Therapeutics
2008-01 – 2009-09 · Symptomatic Neurogenic Orthostatic Hypotension (NOH), Non-diabetic Neuropathy, Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency
What this study did
Parkinson's Disease
Other / comorbidity
NCT01612078 · TSH Biopharm Corporation Limited
2012-06 – 2013-02 · Orthostatic Hypotension
What this study did
Phase 2/3 (2)
Other / comorbidity
NCT00581477 · Vanderbilt University
2004-01 – 2020-12 · Autonomic Nervous System Diseases, Orthostatic Hypotension, Dopamine Beta-Hydroxylase Deficiency, Orthostatic Intolerance
What this study did
NCT02071459 · University Hospital, Toulouse
2014-01-21 – 2019-10-28 · Multiple System Atrophy
What this study did
Phase 2 (12)
Neurogenic Orthostatic Hypotension
NCT03567447 · St. Joseph's Hospital and Medical Center, Phoenix
2018-08-17 – 2020-03-01 · Parkinson Disease, Falls Patient
What this study did
NCT00977171 · Chelsea Therapeutics
2010-07 – 2011-10 · Chronic Fatigue Syndrome, Orthostatic Hypotension, Neurally Mediated Hypotension, Neurogenic Orthostatic Hypotension
What this study did
Parkinson's Disease
NCT03446807 · Loma Linda University
2021-12 – 2023-07-01 · Parkinson Disease, Multiple System Atrophy, Progressive Supranuclear Palsy
What this study did
NCT02812147 · St. Joseph's Hospital and Medical Center, Phoenix
2016-05 – 2019-06 · Parkinson Disease
What this study did
NCT02066571 · Henry Ford Health System
2015-03 – 2017-12 · Parkinson's Disease, Freezing of Gait, Cognitive Ability, General
What this study did
Other / comorbidity
NCT06937307 · Giuseppe Cullaro, MD
2025-05-27 – 2028-12-31 · Acute Kidney Injury, Cirrhosis, Decompensated Cirrhosis of Liver
What this study did
NCT01370512 · Mayo Clinic
2011-11 – 2027-05 · Orthostatic Hypotension
What this study did
NCT02558972 · New York Medical College
2015-09 – 2022-12 · Postural Tachycardia Syndrome (POTS), Vasovagal Syncope (VVS), Fainting
What this study did
NCT02624310 · NYU Langone Health
2016-01 – 2019-01 · HSAN Type IV
What this study did
NCT01323374 · Chelsea Therapeutics
2009-01 – 2011-10 · Fibromyalgia
What this study did
NCT00983814 · Chelsea Therapeutics
2009-10 – 2011-07 · Attention Deficit Hyperactivity Disorder
What this study did
NCT00657046 · Chelsea Therapeutics
2007-12 – 2009-01 · Intradialytic Hypotension
What this study did
Phase 1/2 (5)
Parkinson's Disease
NCT00547911 · National Institute of Neurological Disorders and Stroke (NINDS)
2007-10 – 2013-04 · Parkinson Disease, Multiple System Atrophy, Autonomic Nervous System Diseases
What this study did
NCT01331122 · Chelsea Therapeutics
2012-04 – 2012-12 · Gait Disorders, Neurologic
What this study did
Other / comorbidity
NCT07398508 · Stephen G. Kaler
2026-08-10 – 2030-06-30 · Menkes Disease
What this study did
NCT04977388 · Stephen G. Kaler, MD
2021-07-12 – 2024-06-29 · Menkes Disease, Occipital Horn Syndrome
What this study did
NCT03070730 · Beth Israel Deaconess Medical Center
2011-08-15 – 2014-07-28 · Postural Orthostatic Tachycardia Syndrome, Orthostatic Intolerance
What this study did
Phase 1 (5)
Neurogenic Orthostatic Hypotension
NCT01149629 · Chelsea Therapeutics
2010-07 – 2010-08 · Symptomatic Neurogenic Orthostatic Hypotension
What this study did
Parkinson's Disease
NCT02897063 · Vanderbilt University Medical Center
2016-09 – 2026-10 · Autonomic Failure, Pure Autonomic Failure, Multiple System Atrophy, Parkinson Disease, Orthostatic Hypotension
What this study did
Other / comorbidity
NCT01354158 · Bronx VA Medical Center
2011-05 – 2013-05 · Spinal Cord Injury, Hypotension
What this study did
NCT01468259 · Chelsea Therapeutics
2012-10 – 2012-12 · Renal Disease, End Stage Renal Disease
What this study did
NCT01327066 · Chelsea Therapeutics
2011-03 – 2011-06 · QTc Interval
What this study did
Phase 4 (6)
Neurogenic Orthostatic Hypotension
NCT02586623 · H. Lundbeck A/S
2016-02-11 – 2022-09-09 · Symptomatic Neurogenic Orthostatic Hypotension
What this study did
NCT03229174 · William Ondo, MD
2018-08-23 – 2022-02-02 · Parkinson Disease, Neurogenic Orthostatic Hypotension
What this study did
Parkinson's Disease
NCT04510922 · Alberto Espay, MD, MSc
2019-02-11 – 2020-12-31 · Orthostatic Hypotension, Idiopathic Parkinson Disease
What this study did
NCT03115827 · Vanderbilt University Medical Center
2017-04-18 – 2018-12-21 · Parkinson Disease
What this study did
NCT03034564 · The Cooper Health System
2017-01 – 2018-09-30 · Parkinson Disease, Fatigue, Parkinsonism
What this study did
Other / comorbidity
NCT03602014 · James J. Peters Veterans Affairs Medical Center
2018-06-01 – 2021-12-31 · Hypotension, Orthostatic, Hypotension, Spinal Cord Injuries
What this study did
Early phase / not applicable (2)
Parkinson's Disease
NCT03173781 · Colorado Springs Neurological Associates
2016-04 – 2017-10 · Parkinson's Disease
What this study did
Other / comorbidity
NCT00004478 · Icahn School of Medicine at Mount Sinai
1999-03 – 2006-03 · Shy-Drager Syndrome, Orthostatic Hypotension
What this study did

Competitive landscape

This drug's own stage for Neurogenic Orthostatic Hypotension: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Droxidopa (Northera): this drugApprovedSmall moleculenorepinephrine precursorPartial signal
NCT01176240: 306A Efficacy: Change in Orthostatic Hypotension Questionnaire Score (OHQ) (Baseline, Week 8): Droxidopa -2.2 units on a scale (Standard Deviation 2.44) vs Placebo -2.1 units on a scale (Standard Deviation 2.49)
Ampreloxetine (TD-9855)DiscontinuedSmall moleculenorepinephrine transporterPartial signal
NCT05696717: CYPRESS (NCT05696717), primary endpoint change in OHSA composite score at Week 8: result was not statistically significant. missed
NCT03750552: Change From Baseline in Orthostatic Hypotension Symptom Assessment (OHSA) Question #1 Score at Week 4 (Baseline and Week 4): Ampreloxetine -1.69 score on a scale (Standard Error 0.29) | Placebo -1.45 score on a scale (Standard Error 0.293) missed

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Droxidopa (Northera) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
May 2027 (1)
Phase 2Orthostatic HypotensionEnrolling by invitation
Est. primary completion 2027-05 · NCT01370512 · CT.gov ↗
What to watch
December 2027 (1)
Phase 2Acute Kidney Injury, Cirrhosis, Decompensated Cirrhosis of LiverRecruiting
Est. primary completion 2027-12-31 · NCT06937307 · CT.gov ↗
What to watch
2030 (1)
June 2030 (1)
Phase 1/2Menkes DiseaseRecruiting
Est. primary completion 2030-06-30 · NCT07398508 · CT.gov ↗
What to watch

See the full readout calendar ↗